● Recruiting

A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors

Condition: Advanced Solid Tumor · Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

PhasePhase 1/Phase 2

Planned participants262

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersYes

About this study

This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Chun Wan · 028-86021875 · chun.wan3717@huiyupharma.com

Lin Shen

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University Cancer Hospital

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07083323